...2019, Chakraborty was VP of cell therapy research at Sana Biotechnology Inc. AI drug discovery play Exscientia Ltd....

...European Academy of Neurology meeting. Novo Holdings leads Exscientia’s series C AI drug discovery company Exscientia Ltd....
...contributed to this report. Targets TLR3 - Toll-like receptor 3 Robin Sawka, Staff Writer Robin Sawka, BioCentury Staff Exscientia Ltd. Geron...

...lead candidate RLYB211 for a fetal and neonatal blood disorder; a JV with AI company Exscientia Ltd....
...begin clinical testing of RLYB212 and a second program next year. From its JV with Exscientia...
...discovery. The companies partnered last year to identify small molecule therapies for rare diseases using Exscientia’s...

...pediatric patients two years and older. SRI, Exscientia partner to combine AI with automated chemistry Exscientia Ltd....
...small molecules with automated compound synthesis. The partners will combine SRI’s SynFini chemistry system with Exscientia’s...
...Vascular endothelial growth factor A BioCentury Staff vadadustat (MT-6548, akb-6548) ADVM-022 (AAV.7m8-aflibercept) ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib (TGR-1202, rp5264) SRI International Exscientia Ltd. Tolmar...

...change failure rates in drug development by accessing insights humans can’t find on their own. Exscientia Ltd....
...the target of multiple commercial- and clinical-stage compounds for neuropsychiatric diseases. DSP-1181 was developed using Exscientia’s...
...that formed the basis for its chemistry platform in a 2012 study in Nature . Exscientia...

...were not disclosed. Exscientia, Rallybio form JV for rare disease AI drug discovery AI company Exscientia Ltd....
...joint venture called RE Ventures to identify small molecule therapeutics for undisclosed rare diseases using Exscientia’s...
...HT2RA) - serotonin receptor 2A BioCentury Staff Cimzia, certolizumab pegol (CDP 870) lumateperone (ITI-007) Tamiflu, oseltamivir (GS 4104, Ro 64-0796) Exscientia Ltd. Genentech...

..."Genmab's Blockbuster Darzalex Surpasses $2B in Sales" ). AI play GT Apeiron launches with $27M, Exscientia...
...selection, hit identification, lead optimization, preclinical studies and clinical trials. The start-up also partnered with Exscientia Ltd....
...arc001, peanut allergy oral immunotherapy (oit) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Viaskin Peanut (DBV-712) Aimmune Therapeutics Inc. BiomX Ltd. DBV Technologies S.A. Exscientia Ltd. Genmab...

...Exscientia's platform can generate new candidates more quickly and cheaply than conventional small molecule methods. Exscientia...
...royalties. Celgene participated in Exscientia's $26 million B round as a new investor in January. Exscientia...
...of the financing to build its own internal therapeutics pipeline (see "Exscientia Looks Inward" ). Exscientia...

...spending six years building its artificial intelligence drug discovery platform and working with pharma partners, Exscientia Ltd....
...small portfolio of assets for the same amount of capital,” he told BioCentury. He said Exscientia’s...
...allocation will be building out Exscientia’s capacity. As Chairman Alex Snow noted, four years ago Exscientia...

...Jim Van heusden, who was acting as the company's interim CEO. AI-based drug discovery company Exscientia Ltd....
...Inc. BlueRock Therapeutics Recipharm AB Rewind Therapeutics Swedish Orphan Biovitrum AB Teva Pharmaceutical Industries Ltd. Thermo Fisher Scientific Inc. Alliance for Regenerative Medicine Exscientia Ltd....